These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8411729)

  • 41. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2.
    Stemmer-Rachamimov AO; Ino Y; Lim ZY; Jacoby LB; MacCollin M; Gusella JF; Ramesh V; Louis DN
    J Neuropathol Exp Neurol; 1998 Dec; 57(12):1164-7. PubMed ID: 9862639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The molecular biology and novel treatments of vestibular schwannomas.
    Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
    J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors.
    Louis DN; Ramesh V; Gusella JF
    Brain Pathol; 1995 Apr; 5(2):163-72. PubMed ID: 7670657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.
    Schroeder RD; Angelo LS; Kurzrock R
    Oncotarget; 2014 Jan; 5(1):67-77. PubMed ID: 24393766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neurofibromatosis and associated tumour suppressor genes.
    Zwarthoff EC
    Pathol Res Pract; 1996 Jul; 192(7):647-57. PubMed ID: 8880865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence for a cytoskeleton attachment domain at the N-terminus of the NF2 protein.
    den Bakker MA; Riegman PH; Suurmeijer AP; Vissers CJ; Sainio M; Carpen O; Zwarthoff EC
    J Neurosci Res; 2000 Dec; 62(6):764-71. PubMed ID: 11107160
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors.
    Wolff RK; Frazer KA; Jackler RK; Lanser MJ; Pitts LH; Cox DR
    Am J Hum Genet; 1992 Sep; 51(3):478-85. PubMed ID: 1496981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress toward the isolation and characterization of the genes causing neurofibromatosis.
    Menon AG; Gusella JF; Seizinger BR
    Brain Pathol; 1990 Sep; 1(1):33-40. PubMed ID: 1669691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.
    Warren C; James LA; Ramsden RT; Wallace A; Baser ME; Varley JM; Evans DG
    J Med Genet; 2003 Nov; 40(11):802-6. PubMed ID: 14627667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurofibromatosis type 2 appears to be a genetically homogeneous disease.
    Narod SA; Parry DM; Parboosingh J; Lenoir GM; Ruttledge M; Fischer G; Eldridge R; Martuza RL; Frontali M; Haines J
    Am J Hum Genet; 1992 Sep; 51(3):486-96. PubMed ID: 1496982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NF2 gene in neurofibromatosis type 2 patients.
    Zucman-Rossi J; Legoix P; Der Sarkissian H; Cheret G; Sor F; Bernardi A; Cazes L; Giraud S; Ollagnon E; Lenoir G; Thomas G
    Hum Mol Genet; 1998 Dec; 7(13):2095-101. PubMed ID: 9817927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurofibromatosis 2 and neurilemmomatosis gene are identical.
    Honda M; Arai E; Sawada S; Ohta A; Niimura M
    J Invest Dermatol; 1995 Jan; 104(1):74-7. PubMed ID: 7798645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional analysis of neurofibromatosis 2 (NF2) missense mutations.
    Gutmann DH; Hirbe AC; Haipek CA
    Hum Mol Genet; 2001 Jul; 10(14):1519-29. PubMed ID: 11448944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.
    Ruggieri M; Praticò AD; Serra A; Maiolino L; Cocuzza S; Di Mauro P; Licciardello L; Milone P; Privitera G; Belfiore G; Di Pietro M; Di Raimondo F; Romano A; Chiarenza A; Muglia M; Polizzi A; Evans DG
    Acta Otorhinolaryngol Ital; 2016 Oct; 36(5):345-367. PubMed ID: 27958595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The murine NF2 homologue encodes a highly conserved merlin protein with alternative forms.
    Haase VH; Trofatter JA; MacCollin M; Tarttelin E; Gusella JF; Ramesh V
    Hum Mol Genet; 1994 Mar; 3(3):407-11. PubMed ID: 8012352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
    Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
    Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.
    Lepont P; Stickney JT; Foster LA; Meng JJ; Hennigan RF; Ip W
    Mutat Res; 2008 Jan; 637(1-2):142-51. PubMed ID: 17868749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations.
    Stokowski RP; Cox DR
    Am J Hum Genet; 2000 Mar; 66(3):873-91. PubMed ID: 10712203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurofibromatosis type 2.
    Slattery WH
    Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.